$0.85
2.67% today
Nasdaq, Apr 02, 09:20 pm CET
ISIN
KYG7S53R1049
Symbol
PROK
Sector
Industry

Prokidney Stock price

$0.83
-0.27 24.20% 1M
-0.88 51.32% 6M
-0.86 50.89% YTD
-0.77 48.13% 1Y
-9.06 91.61% 3Y
-9.28 91.79% 5Y
-9.28 91.79% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.05 5.27%
ISIN
KYG7S53R1049
Symbol
PROK
Sector
Industry

Key metrics

Market capitalization $107.51m
Enterprise Value $1.15b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 14,363.13
P/S ratio (TTM) P/S ratio 1,343.88
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $80.00k
EBIT (operating result TTM) EBIT $-178.35m
Free Cash Flow (TTM) Free Cash Flow $-155.86m
Cash position $358.29m
EPS (TTM) EPS $-0.63
P/E forward negative
Short interest 10.10%
Show more

Is Prokidney a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Prokidney Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Prokidney forecast:

2x Buy
40%
3x Hold
60%

Analyst Opinions

5 Analysts have issued a Prokidney forecast:

Buy
40%
Hold
60%

Financial data from Prokidney

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.08 0.08
-
100%
- Direct Costs 4.34 4.34
32% 32%
5,425%
-4.26 -4.26
30% 30%
-5,325%
- Selling and Administrative Expenses 42 42
10% 10%
52,613%
- Research and Development Expense 128 128
20% 20%
159,588%
-174 -174
17% 17%
-217,525%
- Depreciation and Amortization 4.34 4.34
32% 32%
5,425%
EBIT (Operating Income) EBIT -178 -178
18% 18%
-222,940%
Net Profit -61 -61
73% 73%
-76,488%

In millions USD.

Don't miss a Thing! We will send you all news about Prokidney directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prokidney Stock News

Neutral
GlobeNewsWire
16 days ago
WINSTON-SALEM, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results and business highlights for the year ended December 31, 2024.
Neutral
PRNewsWire
2 months ago
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ProKidney Corp. (NASDAQ: PROK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Positive
Seeking Alpha
2 months ago
Rilparencel is ProKidney's main candidate. It is intended as a therapy that stabilizes kidneys, making it potentially useful for CKD patients. We'll have Rilparencel's Phase 2 full data in 2025, as well as the potential confirmation about a “surrogate” endpoint for its Phase 3 trials. Currently, Rilparencel's Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found t...
More Prokidney News

Company Profile

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease (CKD), shifting the emphasis away from management of kidney failure, to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells (SRCs) prepared from a patient's own, autologous, renal cells. The company is headquartered in Winston-Salem, NC.

Head office Cayman Islands
CEO Bruce Culleton
Employees 204
Founded 2015
Website www.prokidney.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today